“Various industry stakeholders have initiated lawsuits against the federal government asserting that the price negotiation provisions of the Inflation Reduction Act are unconstitutional. The impact of these judicial challenges as well as future actions and agency rules implemented by the government on us and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved. Complying with any new legislation and regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business.”
All entries for: Zymeworks
November 7, 2023
Zymeworks
Negative Outlook
Middletown, DE
201-500 employees
201-500 employees
Disease Area: Multiple, Oncology, Therapeutics
Drug Type: Biologic
August 10, 2023
Zymeworks
Negative Outlook
Middletown, DE
201-500 employees
201-500 employees
Disease Area: Multiple, Oncology, Therapeutics
Drug Type: Biologic
May 8, 2023
Zymeworks
Negative Outlook
Middletown, DE
201-500 employees
201-500 employees
Disease Area: Multiple, Oncology, Therapeutics
Drug Type: Biologic
November 8, 2022
Zymeworks
Negative Outlook
Middletown, DE
201-500 employees
201-500 employees
Concerns over Revenue Generation: “The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcarereforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved”
Disease Area: Multiple, Oncology, Therapeutics
Drug Type: Biologic